TABLE 2.
Specimen | No. of specimens positive/total no. of specimens tested (%) |
|||||
---|---|---|---|---|---|---|
Influenza A/B assays (n = 150) |
2009 H1N1 assays (n = 157) |
|||||
CDC | ProFlu+ | MGB | New H1N1 | CDC SW Inf A | CDC SW H1 | |
Influenza A/H1 virusa | 29/29 (100)b | 27/29 (93.1) | 27/29 (93.1) | 0/22 | 0/22 | 0/22 |
Influenza A/H3 virusa | 28/28 (100)c | 28/28 (100) | 28/28 (100) | 0/15 | 0/15 | 0/15 |
Influenza A/2009 H1N1 virusd | 30/30 (100) | 30/30 (100) | 26/30 (86.6) | 100/100 (100) | 99/100 (99) | 97/100 (97) |
Influenza B virus | 30/30 (100) | 30/30 (100) | 29/30 (95) | |||
Influenza virus negative | 0/33 | 0/33 | 0/33 | 0/20 | 0/20 | 0/20 |
Influenza A/H1 and A/H3 subtypes were determined by CDC H1/H3-specific real-time PCR.
One rapid-antigen-positive influenza A/H1 specimen was negative by the R-Mix shell vial culture gold standard.
Two rapid-antigen-positive influenza A/H3 specimens were negative by the R-Mix shell vial culture gold standard.
Influenza A/H1N1 2009 strains used in this study were identified by the Luminex RVP assay as nonsubtypeable influenza A virus. The Luminex RVP assay was considered the gold standard for the 2009 H1N1 assays.